MaaT Pharma announces today the appointment of Dr. Nathalie Corvaïa as Scientific Director. Dr. Corvaïa has over 20 years of experience leading oncology drug research and development programs and their progression to clinical trials. She will be responsible for MaaT Pharma’s non-clinical R&D strategy, including overseeing gutPrint®, the Company’s proprietary AI-based MET drug design and development platform.
“Nathalie brings in-depth and very high-level experience in the research and development of drugs targeting diseases associated with immunity. She joins us as we generate promising preclinical results for our first co-cultivated drug candidate, which aims to improve clinical response in patients with solid tumors treated with immune checkpoint inhibitors,” said Hervé Affagard. , CEO and co-founder of MaaT Pharma. “In this context, Nathalie will play a decisive role in driving and expanding our scientific innovations and our preclinical development strategy. I welcome Nathalie to the management team and look forward to her contribution to the pursuit of our mission, which consists of enabling cancer patients to benefit from innovations resulting from the modulation of the microbiota”.